CMO Tecomet buys Teleflex's ortho unit; Paraxel inks deal with the Korea Drug Development Fund;

 @DamianFierce: A new study says low-income patients are less likely to join cancer trials, raising questions of access and education. More | Follow @DamianFierce

> CMO Tecomet is paying $45.2 million for devicemaker Teleflex's orthopedics unit, a business that pulled in about $36 million last year. News

> Paraxel has signed on with the Korea Drug Development Fund, an outfit worth about $1 billion, to help researchers in that country develop and commercialize new treatments. More

> Battelle has secured a 10-year research contract worth up to $102.5 million from the National Institutes of Health, tasked with carrying out clinical tests of vaccines and biologics designed to halt infectious disease. Article  

> Clinipace is working with Prometheus Laboratories to run trials of Proleukin, the company's candidate melanoma treatment. Item

> PPD continues its managerial shake-up, appointing former Roche exec Louis Renzetti as vice president of strategic laboratory operations. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.

Big Pharma AstraZeneca and academic partner the University of Oxford are tapping research services firm CCT for their COVID-19 shot tests in Arizona.